Skip to main content

Table 2 Comparison of clinical manifestations between AML patients and Foxo3 expression

From: Circ-Foxo3 is positively associated with the Foxo3 gene and leads to better prognosis of acute myeloid leukemia patients

Patient’s parameters High (n = 66) Low (n = 56) P value
Sex, male/female 40/26 34/22 1.0
Median age, years (range) 59 (15–87) 54.5 (10–93) 0.128
Median WBC, ×109/L (range) 14.5 (0.8–528) 26.75 (0.3–197) 0.313
Median hemoglobin, g/L (range) 74.5 (34–138) 78.5 (49–135) 0.134
Median platelets, ×109/L (range) 41 (3–264) 39.5 (5–415) 0.921
BM blasts, % (range) 46.25 (5.5–99) 42 (1–94.5) 0.197
CR (−/+) 33/30 29/24 0.853
FAB classification    0.428
 M0 1 (1.5%) 0 (0%)  
 M1 6 (9.1%) 2 (3.6%)  
 M2 29 (43.9%) 19 (33.9%)  
 M3 8 (12.2%) 15 (26.8%)  
 M4 13 (19.7%) 12 (21.4%)  
 M5 8 (12.1%) 7 (12.5%)  
 M6 1 (1.5%) 1 (1.8%)  
Karyotype classification    0.666
 Favorable 18 (27.3%) 19 (33.9%)  
 Intermediate 37 (56.1%) 28 (50%)  
 Adverse 8 (12.1%) 7 (12.5%)  
 No data 3 (4.5%) 2 (3.6%)  
Karyotype    0.423
 normal 27 (40.9%) 20 (35.7%)  
 t(8;21) 8 (12.1%) 4 (7.1%)  
 t(15;17) 9 (13.6%) 15 (26.8%)  
 11q23 0 (0) 0 (0)  
 complex 8 (12.1%) 5 (8.9%)  
 others 11 (15.2%) 10 (30.4%)  
 No data 3 (4.5%) 2 (3.6%)  
Gene mutation
CEBPA (+/−) 10/51 3/41 0.229
NPM1 (+/−) 4/57 3/41 1.00
FLT3-ITD (+/−) 7/54 5/39 1.00
KIT (+/−) 2/59 2/42 1.00
N/K-RAS (+/−) 8/53 2/42 0.187
IDH1/2 (+/−) 2/59 2/42 1.00
DNMT3A (+/−) 4/57 5/39 0.487
U2AF1 (+/−) 2/59 1/43 1.00
  1. WBC white blood cells, FAB French-American-British classification, AML acute myeloid leukemia, CR complete remission. Percentage was equal to the number of mutated patients divided by total cases in each group